Novartis, CH0012005267

Bank of America keeps CHF 150.00 target for Novartis stock

Published on 10/14/2026 at 17:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis schedules third-quarter results for October 27, 2026. Novartis stock costs EUR 130.94 on October 14, 2026 at Lang & Schwarz.

Analyst target and reporting date

Bank of America Securities maintains a CHF 150.00 target and Buy rating for Novartis.
Novartis schedules third-quarter results for October 27, 2026.
Novartis stock costs EUR 130.94 at Lang & Schwarz on October 14, 2026 at 5:04 p.m. CEST.
The SIX-listed company has a CHF 232.0 billion market capitalization and a P/E ratio of 22.19.

Pharmatechniker an Tablettenpresse, dokumentarische SW-Fotografie mit Industrieatmosphäre — Novartis AG CH0012005267 – Pharmatechniker bedient eine industrielle Tablettenpresse in dokumentarischer Schwarzweißfotografie, Illustration mit AI erstellt.

Bank of America Securities maintains a Buy rating and a CHF 150.00 price target for Novartis, according to TipRanks. Against the SIX quote of CHF 122.04 on October 14, 2026 at 4:53 p.m. CEST, that target lies 22.90 percent above the share price. Novartis stock was trading at EUR 130.94 at Lang & Schwarz on October 14, 2026 at 5:04 p.m. CEST, after the Xetra close.

Results date brings the next test

Novartis has scheduled its third-quarter results for October 27, 2026, according to the company's investor calendar. The date gives investors a defined checkpoint for sales, operating profit and portfolio updates before the company's November capital markets event.

The same calendar lists a remibrutinib multiple-sclerosis investor call for October 23, 2026. That event is scheduled four days before the quarterly release and puts the company's late-stage pipeline back on the calendar.

Revenue and price position

Novartis reported USD 14.95 billion in revenue for the second quarter of 2026, according to MarketBeat. The finance data for the SIX listing put Novartis at CHF 122.04 on October 14, 2026, with a 52-week range of CHF 97.05 to CHF 132.68; the latest price was 8.02 percent below the high.

The Swiss listing carried a P/E ratio of 22.19 and a market capitalization of CHF 232.0 billion on October 14, 2026. Those figures place the analyst target, the upcoming reporting date and the stock's yearly range in one measurable frame.

Comparison with peers

Novartis (SIX, CHF): P/E 22.19, market capitalization CHF 232.0 billion.

Roche (SIX, CHF): plus 0.50 percent, P/E 20.09, market capitalization CHF 256.6 billion.

Sanofi (Euronext Paris, EUR): plus 0.66 percent, P/E 21.98, market capitalization EUR 85.5 billion.

Stock trades after the Xetra close

At Lang & Schwarz, Novartis stock was trading at EUR 130.94 on October 14, 2026 at 5:04 p.m. CEST. The quote came after the Xetra close, while the SIX listing was at CHF 122.04 at 4:53 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Novartis stock.